We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Blocking Copper Function Prevents Restenosis in Arteries

By HospiMedica staff writers
Posted on 19 Jun 2003
Scientists have discovered that the renarrowing of arteries following balloon angioplasty can be halted by copper chelation therapy. More...
Their discovery was reported in the May 27, 2003, issue of the Proceedings of the (US) National Academy of Sciences.

The investigators found that the function of copper is necessary for restenosis, and after angioplasty or stent surgery is performed, the presence of copper cells in artery cells enables the cells to regrow from within the injured vessel. In about 30% of cases, this process reclogs the artery, requiring more surgery. Preventing the function of copper in the body stops the artery from reclogging after angioplasty. The therapy works by limiting the cellular export of growth factors and cytokines involved in this process.

The commonly available reagent TTM (tetrathiomolybdate), which is a specific copper chelator, stopped inflammation and growth of the unwanted new tissue responsible for narrowing the arteries. TTM was able to inhibit the intracellular function of key regulators of cell growth, which normally enable cells to respond to stress.

"This represents a major contribution to medical science,” said Kenneth A. Ault, M.D., director of the Maine Medical Research Institute (MMCRI, Scarborough, USA; www.mmri.org). "This finding could be ready for widespread clinical use in humans in a very few years.”

The research was conducted by a team of scientists from Maine Medical Research Institute (Scarborough, USA) and a team from Dartmouth Hitchcock Medical Center (Lebanon, NH, USA). The discovery is the result of around 15 years of scientific research, said the participants.


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
ow Frequency Pulse Massager
ET10 L
Surgical Headlight
IsoTorch
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.